A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

Cancer Clinical Trial

— TOPOLOGY  

Official title:

A Phase II Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06162351
• Other study ID #: IC 2020-16
• Status: Recruiting
• Phase: Phase 2
• Start date: April 17, 2024
• Est. completion date: March 19, 2026

Study information

• Verified date: May 2024
• Source: Institut Curie
• Contact: Fouzia Azzouz
• Phone: 0147112366
• Email: fouzia.azzouz[@]curie.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single arm phase II study for with primary objective to evaluate the efficacy of PLX038 on response rate for patients with pretreated, metastatic or locally advanced triple negative breast cancer.

Description:

This is an open label, multi-centric phase II study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of PLX038 in locally-advanced or metastatic TNBC. Patient must have received prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, taxane and sacituzumab-govitecan (unless not medically appropriate or contraindicated for the patient) and Received a minimum of two prior cytotoxic chemotherapy regimens for locally advanced or metastatic breast cancer.

Patients will be treated at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection) after at least a first cycle at 1300mg/m2. At the discretion of the treating physician, the PLX038 dose will be increased to 1730 mg/m2 for patients who tolerate at least 1 cycle without any of the following toxicities: febrile neutropenia, grade 4 neutropenia for > 5 days or ANC < 100 109/L for more than 1 day, or other non-hematological toxicities of Grade > 2 [NCI-CTCAE, Version 5].

All included patients will receive PLX038 as single agent as long as study is ongoing or until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.

Tumor assessments must be performed according to the RECIST V1.1 criteria at inclusion and every 8 weeks (± 7 days) from inclusion until documented disease progression, withdrawal of consent, or death. Radiographic measurements must be performed to the RECIST specifications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: March 19, 2026
• Est. primary completion date: August 19, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing and able to comply with the protocol and provide written informed consent prior to study-specific screening procedures.

• Age = 18 years.

• Females and males with cytologically or histologically confirmed breast carcinoma (either the primary or metastatic lesions).

• Locally advanced or metastatic disease that is not amenable to curative treatment.

• Triple negative breast cancer (both ER and PR <10%, HER2-negative or HER2-low).

• Measurable disease (per RECIST version 1.1).

• Prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, taxane and sacituzumab-govitecan (unless not medically appropriate or contraindicated for the patient).

• Received a minimum of two prior cytotoxic chemotherapy regimens for locally advanced or metastatic breast cancer.

• Patients with known gBRCA mutations must have received a PARP inhibitor in the metastatic setting.

• Patients whose cancer has a CPS score =10 must have received prior pembrolizumab unless (i) contra-indicated (ii) CPS score or pembrolizumab not available at time of first line treatment start.

• Resolution of chemotherapy and radiation therapy related toxicities to NCI-CTCAE version 5.0 Grade 1 or lower severity, except for stable sensory neuropathy (= Grade 2), alopecia (any grade), presence of clinically managed chronic autoimmune AEs from prior immune therapy.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate organ function (obtained within 14 days prior to treatment start) as evidenced by:

i. Absolute neutrophil count (ANC) = 1.5 X 109/L; ii. Hemoglobin (Hgb) = 9 g/dL; iii. Platelet count = 100 X 109/L; iv. Bilirubin = 1.5 X upper limit of normal (ULN), except for patients with a documented history of Gilbert's disease (= 2 X ULN); v. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) = 2.5 X ULN (for patients with liver metastases = 5 X ULN); vi. Alkaline phosphatase (AP) = 3 X ULN (for patients with liver metastases, = 5 X ULN); vii. Serum creatinine = 1.5 mg/dL (133 µmol/L) or calculated creatinine clearance = 50 mL/min (using Cockcroft-Gault formula); viii. Women of childbearing potential (WCBP): negative serum pregnancy test.

• Patients covered by social security or health insurance in compliance with the national legislation relating to biomedical research.

Exclusion Criteria:

• Patients who had a last dose of IV chemotherapy within 21 days, last dose of oral cytotoxic chemotherapy, radiotherapy, biological therapy, or investigational therapy within 14 days prior to treatment start.

• Patients who had any major surgery within 28 days prior to inclusion.

• Patients with chronic inflammatory bowel disease and/or bowel obstruction.

• Concomitant use of other agents for the treatment of cancer or any investigational agent(s).

• Brain metastases, unless local therapy was completed and use of corticosteroids for this indication discontinued for at least 3 weeks prior to inclusion. Signs or symptoms of brain metastases must be stable for at least 28 days prior to inclusion. No known progression of brain metastases (by imaging as assessed by RECIST) can have occurred. Patients with leptomeningeal disease or meningeal carcinomatosis are excluded.

• Women who are either pregnant, lactating, planning to get pregnant.

• Patients receiving pharmacotherapy for hepatitis B or C, tuberculosis, or HIV.

• Patients with known liver disease diagnosed with Child-Pugh A or higher cirrhosis.

• Prior stage III or IV malignancy (other than breast cancer).

• Severe/uncontrolled intercurrent illness within the previous 28 days prior to inclusion.

• Significant known cardiovascular impairment (NYHA CHF > grade 2, unstable angina, myocardial infarction within the previous 6 months prior to inclusion, or existing unstable cardiac arrhythmia).

• Any other significant medical, psychological, social or geographic conditions that in the opinion of the Investigator would impair study participation or cooperation.

• Patients deprived of their liberty or under guardianship.

Related Conditions & MeSH terms

• Breast
• Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• PLX038
Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection) after at least a first cycle at 1300mg/m2. Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death.

Locations

Country	Name	City	State
France	Institut Curie	Paris
France	Institut Curie	Saint Cloud

Sponsors (2)

Lead Sponsor	Collaborator
Institut Curie	ProLynx LLC

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best tumor response	Best tumor response (defined as PR or CR in the first 6 months of treatment, assessed by investigators per RECIST v1.1 criteria).	24 weeks
Secondary	Time to response (TTR)	Time to response is defined as the time from inclusion to the first objective tumor response and will be estimated using Kaplan-Meier method	Until 24 months
Secondary	SAEs (all grade, per NCI-CTCAE v5.0)	Serious adverse events (SAEs)according to NCI CTCAE v5.0, by grade and their relationship to PLX038	Until 30 days after the last dose of IMP (24 months + 30 days)
Secondary	Correlation between PLX038 efficacy and homologous recombination (HR) defect (assessed by HR genes mutational status and BCRAness phenotype)	Incidence of efficacy of PLX038 in pre-defined biomarker subgroups (BRCAness)	Until 24 months
Secondary	PK analysis	Maximum Plasma Concentration effect of PLX038	Until 24 months
Secondary	Duration of Response (DoR)	DoR is defined as the time from the first documented PR or CR until the date of disease progression or the date of death. DoR will be computed using Kaplan-Meier	Until 24 months
Secondary	Progression free survival (PFS)	PFS is defined as the time from inclusion to progression (per RECIST 1.1) or death, among included patients	Until 24 months
Secondary	Overall Survival (OS)	PFS is defined as the time from inclusion to the first event among progression and death. OS is defined in the same way but only death is taken into account.	Until 24 months
Secondary	AEs	Adverse events (AEs) according to NCI CTCAE v5.0, by grade and their relationship to PLX038	Until 30 days after the last dose of IMP (24 months + 30 days)
Secondary	Correlation between PLX038 efficacy and homologous recombination (HR) defect, replication stress-related biomarkers such as SFLN11 expression	Incidence of efficacy of PLX038 in pre-defined biomarker subgroups (SLFN11 expression)	Until 24 months
Secondary	Correlation between PLX038 efficacy and homologous recombination (HR) defect replication stress-related biomarkers such as RB1 loss	Incidence of efficacy of PLX038 in pre-defined biomarker subgroups (RB1 loss)	Until 24 months
Secondary	PD analysis	Maximum Plasma Concentration of effect of PLX038	Until 24 months